Ultralife (ULBI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
10 Mar, 2026Executive summary
Q4 2025 revenue reached $48.5 million, up 10.6% year-over-year, with a full-year total of $191.2 million, a 16.2% increase year-over-year.
Backlog grew to $110.2 million, up 22% sequentially, diversified across markets, with over $6 million from new 2025 product launches.
Operating loss for Q4 was $10.6 million, driven by a $12.2 million non-cash intangible asset impairment and $1.2 million in one-time costs; full-year operating loss was $5.9 million.
Adjusted EBITDA for Q4 was $5.7 million (11.7% of sales), up from $3.9 million (8.9%) last year.
Completed ERP transition, closed two North American facilities, and unified back-office systems.
Financial highlights
Battery and energy product segment Q4 revenue was $45.9 million, up 15.1% year-over-year; organic growth was 9.5%.
Communications Systems segment revenue declined 35.2% to $2.6 million due to delayed government orders.
Consolidated gross profit was $12.1 million, up 13.7% year-over-year; gross margin improved to 24.9%.
Net loss for Q4 was $7.4 million or $0.45 per share, including $0.57 per share for the impairment charge.
Cash balance at year-end was $9.3 million, up from $6.9 million a year earlier.
Outlook and guidance
Entering 2026 with a strong backlog and improved operational efficiency, positioning for profitable growth and incremental cash flow.
Communications Systems expected to rebound in 2026 as new products launch and delayed programs resume.
Targeting organic growth at least 2x GDP and short-term EBITDA margin above 10%.
Baseline revenue goal for Communications Systems is $25 million, with potential for large orders.
Plans to reduce debt, support strategic capital expenditures, and invest in new product development.
Latest events from Ultralife
- Gross margin and adjusted EBITDA rose in Q2 2026, with backlog at a record high.ULBI
Q2 2026 - Annual meeting to vote on directors, auditor ratification, and executive pay proposals.ULBI
Proxy filing - Proxy covers director elections, auditor ratification, compensation, and governance priorities.ULBI
Proxy filing - Revenue and margins declined, but a record $115.1 million backlog and new products support future growth.ULBI
Q1 2026 - Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 2025 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 2024 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 2024 - Q1 2025 revenue up 21% to $50.7M, but net income and margins declined on higher costs.ULBI
Q1 2025 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 2024